Hamlin P, Farber C, Fenske T, et al. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/refractory B cell malignancies. EHA 2017, abstract S773.
Preoperatieve intraveneuze of orale ijzersuppletie bij patiënten met colorectaal carcinoom
mei 2023 | Benigne hematologie, Chirurgie, Maag-darm-leveroncologie